Clinical trial
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Active, not recruiting · Phase 3 · 2 countries · Registry ID NCT07232719
Active, not recruitingPhase 3Interventional
What this study is about
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Overweight
Full registry criteria
Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
Treatments and study arms
Retatrutide
Drug
Administered SC
Placebo
Drug
Administered SC
Primary outcomes
Percent Change from Baseline in Body WeightBaseline, Week 56
Study locations
31 locations were listed when this page was built. The first 40 are shown.
FutureMeds - Birmingham🇬🇧 Birmingham, United Kingdom
Layton Medical Centre🇬🇧 Blackpool, United Kingdom
Bradford on Avon Health Centre🇬🇧 Bradford-on-Avon, United Kingdom
FutureMeds - Liverpool🇬🇧 Bromborough, United Kingdom
Cheadle Community Hospital🇬🇧 Cheadle, United Kingdom
HMC Health Group - Meadows Centre for Health🇬🇧 Hounslow, United Kingdom
St Bartholomew's Medical Centre🇬🇧 Oxford, United Kingdom
Atlantic Medical🇬🇧 Penzance, United Kingdom
The Adam Practice🇬🇧 Poole, United Kingdom
Woodstock Bower Surgery🇬🇧 Rotherham, United Kingdom
Rame Group Practice🇬🇧 Torpoint, United Kingdom
Albany House Medical Centre🇬🇧 Wellingborough, United Kingdom
Care Access - Arlington Heights🇺🇸 Arlington Heights, Illinois, United States
JEM Research Institute🇺🇸 Atlantis, Florida, United States
Pharmasite Research, Inc.🇺🇸 Baltimore, Maryland, United States
Clinical Research Professionals🇺🇸 Chesterfield, Missouri, United States
Cedar Health Research🇺🇸 Dallas, Texas, United States
Headlands Research-El Paso🇺🇸 El Paso, Texas, United States
Cedar Health Research - Euless🇺🇸 Euless, Texas, United States
Cedar Health Research - Fort Worth🇺🇸 Fort Worth, Texas, United States
Care Access - Houston🇺🇸 Houston, Texas, United States
L-MARC Research Center🇺🇸 Louisville, Kentucky, United States
IMA Clinical Research Monroe - Armand🇺🇸 Monroe, Louisiana, United States
IMA Clinical Research Manhattan🇺🇸 New York, New York, United States
Headlands Research Orlando🇺🇸 Orlando, Florida, United States
Artemis Institute for Clinical Research🇺🇸 Riverside, California, United States
IMA Clinical Research San Antonio🇺🇸 San Antonio, Texas, United States
Clinvest Headlands Llc🇺🇸 Springfield, Missouri, United States
Care Access - Tamarac🇺🇸 Tamarac, Florida, United States
IMA Clinical Research Warren🇺🇸 Warren Township, New Jersey, United States
Trial Management Associates - Wilmington - Floral Parkway🇺🇸 Wilmington, North Carolina, United States